Millicent patents expiration
1. Femring patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5855906 | MILLICENT | Intravaginal drug delivery devices for the administration of 17β-oestradiol precursors |
Dec, 2015
(8 years ago) | |
Drugs and Companies using ESTRADIOL ACETATE ingredient
Market Authorisation Date: 20 March, 2003
Treatment: Method of releasing 17-beta oestradiol precursor in a substantially zero order pattern for at least three weeks
Dosage: INSERT, EXTENDED RELEASE;VAGINAL
More Information on Dosage
FEMRING family patents
2. Intrarosa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8629129 | MILLICENT | Pharmaceutical compositions |
Aug, 2028
(4 years from now) | |
| US8957054 | MILLICENT | Pharmaceutical compositions |
Jan, 2030
(5 years from now) | |
| US8268806 | MILLICENT | Pharmaceutical compositions |
Mar, 2031
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 16, 2021 |
Drugs and Companies using PRASTERONE ingredient
NCE-1 date: 16 November, 2020
Market Authorisation Date: 16 November, 2016
Treatment: Intravaginal prasterone (dehydroepiandrosterone) at a daily dose of 6.5mg for the treatment of dyspareunia, a symptom of vulvar and vaginal atrophy, due to menopause
Dosage: INSERT;VAGINAL
More Information on Dosage
INTRAROSA family patents